Tag: pcsk9

1. In this case report, two patients who developed statin-associated autoimmune myopathy had their cholesterol levels effectively managed with the novel cholesterol reduction medication evolocumab. 2. The use of this drug did not result in any adverse events for the two patients included in the case study throughout follow-up. Evidence...
1. In this systematic review and meta-analysis, more intensive compared with less itensive LDL-C lowering was associated with a greater reduction in risk of total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels. 2. The greatest benefit from LDL-C lowering therapy occurred for patients with baseline...
1. In addition to significantly lowering levels of low density lipoprotein cholesterol (LDL-C), evolocumab reduced the composite risk of cardiovascular events in atherosclerotic patients on optimal statin therapy without a significant increase in adverse effects. 2. As individual endpoints, evolocumab did not significantly reduce the rate of either cardiovascular or...
1. When added to statin therapy, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor bococizumab significantly reduced the risk of cardiovascular events in patients with low density lipoprotein cholesterol (LDL-C) levels greater than 100 mg/dL, but had no benefit in patients with LDL-C lower than 100 mg/dL. 2. Combined analyses,...
1. This multi-year, open-label extension of phase 2 trials examining the LDL-lowering efficacy of evolocumab (PCSK9-inhibitor) showed that evolocumab plus standard of care lipid lowering therapy had continued lipid lowering response after over four years of follow-up. 2. Significant adverse events, including new-onset diabetes, neurocognitive complications, or development of neutralizing...
1. Among patients with muscle-related statin intolerance, evolocumab reduced LDL-C levels significantly more than ezetimibe. 2. Evolocumab and ezetimibe had similar rates of muscle-related adverse events when compared to statins. Evidence Rating Level: 1 (Excellent) Study Rundown: Statin therapy has been shown to be effective in reducing cholesterol levels in patients with...
1. From a systematic review, proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies significantly reduced LDL cholesterol levels and all-cause mortality without an increase in serious adverse events. 2. PCSK9 antibodies were also associated with a decreased risk for myocardial infarction in patients with dyslipidemia. Evidence Rating Level: 1 (Excellent) Study Rundown: Dyslipidemia...